Orphan drugs: expensive yet necessary
- PMID: 26337658
- PMCID: PMC4888322
- DOI: 10.1093/qjmed/hcv150
Orphan drugs: expensive yet necessary
Similar articles
-
Orphan drugs: expensive yet necessary.QJM. 2015 Apr;108(4):269-72. doi: 10.1093/qjmed/hcu240. Epub 2014 Nov 28. QJM. 2015. PMID: 25434052
-
Drugs for rare diseases: mixed assessment in Europe.Prescrire Int. 2007 Feb;16(87):36-42. Prescrire Int. 2007. PMID: 17323539
-
A comparative study of orphan drug prices in Europe.J Mark Access Health Policy. 2017 Mar 29;5(1):1297886. doi: 10.1080/20016689.2017.1297886. eCollection 2017. J Mark Access Health Policy. 2017. PMID: 28473887 Free PMC article.
-
Saving orphan drug legislations: misconceptions and clarifications.Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):111-7. doi: 10.1586/14737167.2016.1141052. Expert Rev Pharmacoecon Outcomes Res. 2016. PMID: 26768506 Review.
-
Drugs for exceptionally rare diseases: do they deserve special status for funding?QJM. 2005 Nov;98(11):829-36. doi: 10.1093/qjmed/hci128. Epub 2005 Oct 3. QJM. 2005. PMID: 16203824 Review.
References
-
- Hyry HI, Roos JCP, Cox TM. Orphan drugs: expensive yet necessary. QJM 2015; 108:269–72. - PubMed
-
- Hyry HI, Stern AD, Cox TM, Roos JCP. Limits on use of health economic assessments for rare diseases. QJM 2014; 107:241–5. - PubMed
-
- Müller-Hill B. Murderous Science: Elimination by Scientific Selection of Jews, Gypsies, and Others in Germany 1933-45. Oxford, Oxford University Press, 1998.
-
- Andersson H, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008; 122:1182–90. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources